PDE-5 inhibitors increase risk of biochemical recurrence after radical prostatectomy
the ONA take:
According to a new study published in The Journal of Urology, researchers have found that taking phosphodiesterase type 5 inhibitors following radical prostatectomy is associated with an elevated risk of biochemical recurrence.
Phosphodiesterase type 5 inhibitors include sildenafil, tadalafil, and vardenafil, and are indicated for the treatment of pulmonary hypertension and erectile dysfunction.
Researchers at University Hospital Hamburg-Eppendorf in Hamburg, Germany, sought to investigate the effect of phosphodiesterase type 5 inhibitors on biochemical recurrence following a radical prostatectomy in patients with prostate cancer.
Researchers analyzed data from nearly 5,000 patients with localized prostate cancer who underwent bilateral nerve-sparing radical prostatectomy. Of those, 23.4% used phosphodiesterase type 5 inhibitors following surgery.
During a median follow-up of 60.3 months, there was a 5-year biochemical recurrence-free survival of 84.7% in the phosphodiesterase type 5 inhibitor group compared with 89.2% in the nonphosphodiesterase type 5 inhibitor group. Multivariate analysis showed that phosphodiesterase type 5 inhibitor use was an independent risk factor for biochemical recurrence (HR = 1.38).
Taking phosphodiesterase type 5 inhibitors following radical prostatectomy is associated with an elevated risk of recurrence.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|